Industry News

- Read more about US FDA accepts Immune Pharma's Bertilimumab IND application for treatment of Bullous Pemphigoid
Immune Pharmaceuticals Inc. announced that the US Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for its first in class, lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP). This FDA acceptance enables the company to expand recruitment for its clinical trials.
- Read more about U.S. FDA approves New Indications for Harvoni®, Gilead's chronic hepatitis C drug
Drugmaker Gilead Sciences Inc said U.S. Food and Drug Administration had approved the expanded use of its blockbuster hepatitis C drug, Harvoni. The drug can now be used to treat patients with subtypes of chronic hepatitis C virus (HCV) and patients who are co-infected with Human Immunodeficiency Virus (HIV), Gilead said in a statement. Gilead's Harvoni was first approved by the FDA in October 2014.
- Read more about Boehringer Ingelheim announces completed enrollment of phase III clinical trial for biosimilar candidate to Adalimumab
Boehringer Ingelheim today announced it has completed enrollment for the pivotal Phase III trial of BI695501, a biosimilar candidate to adalimumab (AbbVie’s Humira®). This announcement was made following recent results from a Phase I trial that demonstrated pharmacokinetic bioequivalence with both the U.S.-licensed and EU-approved reference products.These Phase I data for BI695501 were discussed at the American College of Rheumatology / Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in San Francisco.
- Read more about UBM India is all set to host the Annual Pharma Awards 2015
UBM India is all set to host the 3rd Annual India Pharma Awards scheduled on 30th November, 2015 at ITC Maratha, Mumbai and pleased to announce TAKE Solutions as our presenting partner. The event is more than an ‘Award Night’ and it will bring together the luminaries of the Pharmaceutical Industry combined with a night of glamour, entertainment, jubilation and the pride of being the crème de la crème of the Indian Pharmaceutical sector.
- Read more about India aims for at least 1500 biotech start-ups
India aims to scale up start-ups in the biotechnology sector to at least 1,500 in the next two to three years to boost technological interventions in the health and agriculture sectors, a senior biotechnology department official said.
- Read more about WuXi PharmaTech and Lilly announce strategic collaboration to develop novel therapeutic in China
WuXi PharmaTech (Cayman) Incand Eli Lilly and Company announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.
- Read more about FDA approves Cotellic as combination treatment for advanced melanoma
The U.S. Food and Drug Administration approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

[adsense:336x280:8701650588]
- Read more about DS Biopharma receive European patent covering the use of DS102 to treat fatty liver disorders
DS Biopharma, a biopharmaceutical company, announced that its patent covering the use of bioactive active pharmaceutical ingredient (API) DS102 (15-HEPE) for fatty liver disorders has been granted by the European Patent Office (EPO).
- Read more about Indian vaccine for meningitis hailed in Africa
Five years after the introduction of MenAfriVac, an affordable vaccine for meningitis A produced by Indian firm Serum Institute of India, immunization has led to the near elimination of the deadly disease in Africa's 'meningitis belt', says the Clinical Infectious Diseases journal.
- Read more about Abcam acquires US antibody research firm AxioMx
Abcam, a supplier of life science research tools, is to acquire AxioMx, an American antibody technology firm, for US$25m. The firm, based in Cambridge, UK has agreed the deal and will pay $20m to AxioMx with further performance payments of up to $5m over five years. The deal is expected to be completed by the end of this month.